The estimated Net Worth of Harry Stylli is at least 12.9 百万$ dollars as of 2 December 2020. Harry Stylli owns over 152,905 units of Progenity stock worth over 12,862,849$ and over the last 4 years Harry sold PROG stock worth over 0$.
Harry has made over 3 trades of the Progenity stock since 2020, according to the Form 4 filled with the SEC. Most recently Harry bought 152,905 units of PROG stock worth 499,999$ on 2 December 2020.
The largest trade Harry's ever made was buying 152,905 units of Progenity stock on 2 December 2020 worth over 499,999$. On average, Harry trades about 24,530 units every 21 days since 2020. As of 2 December 2020 Harry still owns at least 14,616,874 units of Progenity stock.
You can see the complete history of Harry Stylli stock trades at the bottom of the page.
Harry's mailing address filed with the SEC is C/O PROGENITY, INC., 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO, CA, 92122.
Over the last 4 years, insiders at Progenity have traded over 0$ worth of Progenity stock and bought 34,001,547 units worth 176,045,049$ . The most active insiders traders include Capital Management, Lp Ferr...、Opportunities Fund (A) Lp A...、Opportunities Fund (A) Lp A.... On average, Progenity executives and independent directors trade stock every 24 days with the average trade being worth of 1,994,758$. The most recent stock trade was executed by Capital Management, Lp Ferr... on 14 June 2021, trading 8,097,166 units of PROG stock currently worth 20,000,000$.
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Progenity executives and other stock owners filed with the SEC include: